Sir Dr Sobczak et al reported that intravenous L-tryptophan (L-Trp) in first-degree relatives of patients with bipolar disorder (BD) leads to cognitive deficits in executive function and attention compared to healthy control subjects. The authors suggest that impairment in these domains may reflect a central vulnerability of the serotonergic system in frontal brain regions and possible involvement in the cognitive sequelae of BD. The authors also report that in BD relatives and controls, L-Trp impaired delayed memory performance and psychomotor function. For the former group, L-Trp appears to have impaired memory due to a disruption in learning and/or memory consolidation, while for the control group their learning ability was unaffected.
An important consideration with regard to neurochemical specificity is whether the cognitive deficits in BD relatives are entirely attributable to an enhanced serotonergic function following L-Trp. It is well known that large neutral amino acids such as tryptophan, tyrosine and phenylalanine compete for the same blood-brain barrier transporter. A number of studies have shown that infusion of L-Trp can reduce the ratio of tyrosine to large neutral amino acids (Heuther et al, 1992) , biochemical markers of dopamine synthesis (Hashiguti et al, 1993) , and dopaminergic behavioral responses (Molina et al, 2001) . It is therefore possible that the impairments in cognitive function following L-Trp may be partially explained by an indirect effect on reducing central dopamine turnover. Further, dopamine has been shown to modulate neuroendocrine responses such as prolactin and growth hormone release (Lal, 1988) and cognitive processes such as working memory (Ellis and Nathan, 2001) , attention and executive function (Robbins, 2000) , which are also domains affected by L-Trp infusion (Charney et al, 1982; Luciana et al, 2001; Sobczak et al, 2003) . This suggests that the physiological and behavioral effects of L-Trp administration in first-degree BD relatives may be mediated by both serotonergic and dopaminergic mechanisms.
Independent of L-Trp infusion, the BD relatives showed deficits in memory, attention, and psychomotor function compared to controls to which the authors suggest may represent cognitive-trait marker of this illness. It is also evident that the cognitive deficit and clinical symptoms of BD are mediated in part by abnormalities of the mesocortical dopamine system. For example, patients with BD show primary deficits in executive function, such as planning, problem solving, abstract concept formation, set-shifting, and working memory (Quraishi and Frangou, 2002) , which have been linked to the neuromodulatory influence of mesocortical dopamine activity. Supporting this link, recent studies have reported an improvement in acute manic symptoms following dopamine precursor depletion (McTavish et al, 2001; Scarna et al, 2003) , while tryptophan depletion has been demonstrated to have no significant effects on cognitive symptoms in euthymic BD patients (Hughes et al, 2002) .
While the study by Sobczak et al (2003) is an important finding showing cognitive deficits following L-Trp infusion in first-degree relatives of BD patients, further studies are needed to determine if the effects are entirely attributable to enhancement of serotonergic function, as it is likely that dopaminergic mechanisms may in part be responsible for some of the cognitive deficits associated with this challenge.
